BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

Limiting the inflammatory side effects of adjuvanted vaccinesA team led by University of Chicago scientists reported in Science Advances that NF-κB modulator SN50 could enable the use of adjuvants to amplify adaptive immune response by...
BioCentury | Aug 25, 2020
Product Development

Aug. 24 Quick Takes: Setbacks for Novartis, Odonate, Onconova, Tricida; plus upcoming adcomm for Alkermes, and Sinopharm’s vaccine

Novartis’ PD-1 misses in melanoma comboNovartis AG (NYSE:NVS; SIX:NOVN) said spartalizumab missed the primary endpoint of the Phase III COMBI-i trial in patients with untreated, unresectable BRAF V600-mutant cutaneous melanoma. The PD-1 inhibitor, in combination...
BioCentury | Oct 24, 2019

GCase activator reduces α-synuclein in mouse, patient-derived models of PD

DISEASE CATEGORY: Neurology INDICATION: Parkinson's disease (PD) Northwestern University researchers, including Lysosomal Therapeutics Inc. co-founder Dimitri Krainc, developed a small molecule GCase activator that could treat Parkinson’s disease. Mutations in GCase, a lysosomal enzyme, are...
BioCentury | Jan 5, 2018
Clinical News

Odonate starts Phase III trial of tesetaxel to treat breast cancer

Odonate Therapeutics Inc. (NASDAQ:ODT) began the Phase III CONTESSA trial of tesetaxel (DJ-927) to treat locally advanced or metastatic breast cancer. The open-label, international trial will compare 27 mg/m 2 oral tesetaxel once every 21...
BioCentury | Feb 17, 2017
Targets & Mechanisms

Gilding the Goldfinch

...Xortx Pharma Corp. Oxypurinol Small molecule xanthine oxidase inhibitor PKD Phase II 3SBio Inc. (HKSE:1530) DJ5...
BioCentury | Feb 9, 2017
Tools & Techniques

Preclinical autopilot

A new wave of CROs is marrying robotics, software automation and online tools to offer remote-control laboratory services, aiming to upend preclinical research by taking human error out of the equation and amplifying productivity. The...
BioCentury | Oct 20, 2016
Product R&D

Chaperoning the DJ

In the latest example of post-dopamine thinking in Parkinson’s disease, Cantabio Pharmaceuticals Inc. has moved upstream of the neurotransmitter with a strategy to block the protein misfolding and oxidative damage that drive neurodegeneration in the...
BioCentury | Aug 1, 2016
Company News

Cantabio, Purdue University deal

Cantabio and the university’s Purdue Research Foundation partnered to evaluate small molecule chaperone candidates from the biotech that target DJ-1 (PARK7) to treat neurodegenerative diseases, including Parkinson’s disease (PD). Cantabio will have access to resulting...
BioCentury | Jun 27, 2016
Company News

Cantabio, University of Antioquia deal

Cantabio and the university’s Neuroscience Research Group will evaluate Cantabio’s small molecule chaperone therapeutic candidates targeting DJ-1 (PARK7) to treat Parkinson’s disease (PD). The partners are focusing on protective effects of Cantabio’s candidates and cellular...
BioCentury | Aug 6, 2015
Distillery Therapeutics

Therapeutics: DJ-1 (PARK7)

Endocrine/metabolic disease INDICATION: Obesity Cell culture and mouse studies suggest inhibiting DJ-1 could help treat obesity. In mice, a high-fat diet increased muscle levels of DJ-1 mRNA compared with a normal diet. In cultured mouse...
Items per page:
1 - 10 of 140